[1] 刘桂勇. 盐敏感性高血压的治疗[J]. 大家健康, 2012, 6(5): 92-94. [2] Blaustein MP, Leenen FH, Chen L, et al. How NaCl raises blood pressure: a new paradigm for the pathogenesis of salt-dependent hypertension[J]. Am J Physiol Heart Circ Physiol, 2011, 302(5): H1031-1049. [3] 牟建军, 刘治全. 盐敏感性高血压药物治疗选择[J]. 中华高血压杂志, 2012, 20(3): 216-218. [4] 余劼, 许奇, 王毅群. 腺苷受体调节睡眠觉醒作用机制进展[J]. 中国临床药理学与治疗学, 2011, 16(2): 214-218. [5] Jackson EK, Zhu C, Tofovic SP. Expression of adenosine receptors in the preglomerular microcirculation[J]. Am J Physiol Renal Physiol, 2002, 283(1): F41-51. [6] Oppermann M, Qin Y, Lai EY, et al. Enhanced tubuloglomerular feedback in mice with vascular overexpression of A1 adenosine receptors[J]. Am J Physiol Renal Physiol, 2009, 297(5): F1256-1264. [7] Vitzthum H, Weiss B, Bachleitner W, et al. Gene expression of adenosine receptors along the nephron[J]. Kidney Int, 2004, 65(4): 1180-1190. [8] Al-Mashhadi RH, Skott O, Vanhoutte PM, et al. Activation of A2 adenosine receptors dilates cortical efferent arterioles in mouse[J]. Kidney Int, 2009, 75(8): 793-799. [9] Singh P, Thomson SC. Renal homeostasis and tubuloglomerular feedback[J]. Curr Opin Nephrol Hypertens, 2010, 19(1): 59-64. [10] Ledent C, Vaugeois JM, Schiffmann SN, et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor[J]. Nature, 1997, 388(6643): 674-678. [11] Wei Y, Sun P, Wang Z, et al. Adenosine inhibits ENaC via cytochrome P-450 epoxygenase-dependent metabolites of arachidonic acid[J]. Am J Physiol Renal Physiol, 2006, 290(5): F1163-1168. [12] Carlström M, Wilcox CS, Welch WJ. Adenosine A2A receptor activation attenuates tubuloglomerular feedback responses by stimulation of endothelial nitric oxide synthase[J]. Am J Physiol Renal Physiol, 2011, 300(2): F457-464. [13] Carlström M, Wilcox CS, Welch WJ. Adenosine A2 receptors modulate tubuloglomerular feedback[J]. Am J Physiol Renal Physiol, 2010, 299(2): F412-417. [14] Yap SC, Lee HT. Adenosine and protection from acute kidney injury[J]. Curr Opin Nephrol Hypertens, 2012, 21(1): 24-32. [15] Kim SM, Mizel D, Huang YG, et al. Adenosine as a mediator of macula densa-dependent inhibition of renin secretion[J]. Am J Physiol Renal Physiol, 2006, 290(5): F1016-1023. [16] Williams JM, Murphy S, Burke M, et al. 20-Hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension[J]. J Cardiovasc Pharmacol, 2010, 56(4): 336-344. [17] McGiff JC, Quilley J. 20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure[J]. Curr Opin Nephrol Hypertens, 2001, 10(2): 231-237. [18] Elmarakby AA. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease[J]. Am J Physiol Regul Integr Comp Physiol, 2012, 302(3): R321-330. [19] Imig JD, Pham BT, LeBlanc EA, et al. Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses[J]. Hypertension, 2000, 35(1 Pt 2): 307-312. [20] Capdevila JH, Wei S, Yan J, et al. Cytochrome P-450 arachidonic acid epoxygenase. Regulatory control of the renal epoxygenase by dietary salt loading[J]. J Biol Chem, 1992, 267(30): 21720-21726. [21] Cheng MK, Doumad AB, Jiang H, et al. Epoxyeicosatrienoic acids mediate adenosine-induced vasodilation in rat preglomerular microvessels (PGMV) via A2A receptors[J]. Br J Pharmacol, 2004, 141(3): 441-448. [22] Liclican EL, McGiff JC, Pedraza PL, et al. Exaggerated response to adenosine in kidneys from high salt-fed rats: role of epoxyeicosatrienoic acids[J]. Am J Physiol Renal Physiol, 2005, 289(2): F386- 392. [23] Carroll MA, Balazy M, Margiotta P, et al. Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides[J]. Am J Physiol, 1996, 271(4 Pt 2): R863-869. [24] Nayeem MA, Poloyac SM, Falck JR, et al. Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice[J]. Am J Physiol Heart Circ Physiol, 2008, 295(5): H2068- 2078. [25] Nayeem MA, Ponnoth DS, Boegehold MA, et al. High-salt diet enhances mouse aortic relaxation through adenosine A2A receptor via CYP epoxygenases[J]. Am J Physiol Regul Integr Comp Physiol, 2009, 296(3): R567-574. [26] Liclican EL, McGiff JC, Falck JR, et al. Failure to upregulate the adenosine2A receptor- epoxyeicosatrienoic acid pathway contributes to the development of hypertension in Dahl salt-sensitive rats[J]. Am J Physiol Renal Physiol, 2008, 295(6): F1696-1704. [27] Lee CR, North KE, Bray MS, et al. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study[J]. Pharmacogenet Genomics, 2007, 17(5): 349-358. [28] Huang H, Chang HH, Xu Y, et al. Epoxyeicosatrienoic acid inhibition alters renal hemodynamics during pregnancy[J]. Exp Biol Med (Maywood), 2006, 231(11): 1744-1752. [29] Guimarães S, Albino-Teixeira A. Hypertension due to chronic blockade of P1-purinoceptors[J]. J Auton Pharmacol, 1996, 16(6): 367-370. [30] Kunes J, Zicha J, Jelínek J. The role of chloride in deoxycorticosterone hypertension: selective sodium loading by diet or drinking fluid[J]. Physiol Res, 2004, 53(2): 149-154. |